Bausch + Lomb's LuxLife IOL receives CE Mark approval in Europe

News
Article

The LuxLife full range of vision intraocular lens is available in a range of cylinders spanning from +0.75D to +6.00D.

Graphic of CE Marks Image credit: AdobeStock/AndreasPrott

Bausch + Lomb is expecting LuxLife IOLs to be commercially available in Europe in the coming weeks, with a toric version of the lens to follow. Image credit: AdobeStock/AndreasPrott

Bausch + Lomb has announced CE Mark approval for its LuxLife full range of vision intraocular lens (IOL).1 The preloaded, non-diffractive IOL utilizes Pure Refractive Optics (PRO) technology in order to provide continuous vision for the entire optical diameter and from distance to near, according to a news release.

The company stated in the release that the announcement “reinforces Bausch + Lomb’s commitment to equip cataract surgeons with choices to fit the right lens to the right patient following the recent launches of enVista Envy full range of vision lenses in the United States and Canada and enVista Aspire intermediate-optimized IOLs in Europe.”

“This platform has delivered both quality of vision and patient satisfaction since its introduction,” said Luc Bonnefoy, president of Surgical at Bausch + Lomb, in the release. “LuxLife is an example of how we plan to build on that success by developing premium options designed to meet the evolving needs of surgeons and patients.”

The LuxLife IOL is available in a range of cylinders spanning from +0.75D to +6.00D, which enables surgeons to treat the 79.5% of patients that have more than 0.5D of corneal astigmatism prior to their cataract surgery. Surgeons are also provided options in terms of injection technique during implantation with LuxLife’s preloaded, versatile dual injector system.1

A multicenter, comparative clinical study recently evaluated the LuxLife IOL as compared to the monofocal LuxGood IOL and found that patients experienced excellent binocular visual outcomes with LuxLife at near, intermediate, and far distances. The lens also demonstrated high patient satisfaction levels, with 95.6% reporting spectacle independence at intermediate distance and 89.5% at near.1

The IOL is also equipped with 2 unique Allied Ray Technology (ART) Zones which can control and refocus light rays. According to the release, the PRO technology and ART Zones allow the lens to maintain light to the retina.1

"The LuxLife lens provides truly multifocal optical performance, offering an extensive range of clear vision from distance to near,” said Francisco Javier Castro Alonso, MD, PhD, of UFR-Miguel Servet University Hospital in Zaragoza, Spain, an investigator in the multicenter clinical study, in the release. “I consider this lens a first-choice option for patients seeking freedom from glasses at all distances.”

Bausch + Lomb is expecting LuxLife IOLs to be commercially available in Europe in the coming weeks, with a toric version of the lens to follow. Submissions for regulatory approvals in other countries are currently ongoing.1

Reference:
  1. Bausch + Lomb receives European CE Mark approval for preloaded LuxLife full range of vision intraocular lens. News release. May 7, 2025. Accessed May 8, 2025. https://www.bausch.com/newsroom/news/?id=260

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Robert Maloney, MD, MA, at the 2025 Controversies in Modern Eye Care meeting
At CIME 2025, Selina McGee, OD, FAAO, says some patients underestimate oculoplastic care. She stands in front of a sign that says Controversies in Modern Eye Care 2025.
At ASCRS 2025, Alex Hacopian, MD, shares information from his presentation on next-gen presbyopia-correcting intraocular lenses.
Rhue and Canto-Sims talk the value of contact lens patients, financial insights, and key benefits of implementing a contact lens management system.
Drs Brianna Rhue and Diana Canto-Sims discuss the benefits of implementing a contact lens management system that can help improve lens sales at your practice.
Matt Jones, OD; Matt Burns; and Joe Sugg, OD; detailed what optometrists can expect to change when HB 1353's regulations are enacted later this year.
Dana Shannon, OD, FAAO, shares pearls on spotting red flags in need of referral and enhancing patient care with follow-up compliance.
Dana Shannon, OD, FAAO, detailed a lecture she gave at the NOA Midwestern Symposium earlier this month.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, gave 2 presentations alongside other ODs and MDs at CRU 2025.
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
© 2025 MJH Life Sciences

All rights reserved.